Glioblastoma is the most common and aggressive primary malignant brain tumour. Due to the lack of effective treatment options, Cancer Research UK has included glioblastoma in the category of ‘cancers of substantial unmet need’. Our goal is to improve clinical outcomes for patients with glioblastoma, from pre-clinical development of novel therapies to early and later phase clinical trials.